logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Bristol-Myers Squibb Compnay


USPTO Granted Patents = 3,699



Trademarks = 101

Forward Citations = 45,969

Loading Chart...
Loading Chart...

3,428 inventors (with patents filed for the assignee):

goldMedal Nicholas A Meanwell (120 out of 141 patents)

silverMedal John E Macor (111 out of 118 patents)

bronzeMedal John F Kadow (106 out of 136 patents)

4.  Paul Michael Scola (85 out of 87 patents)

5.  William R Ewing (70 out of 85 patents)

6.  Tao Wang (66 out of 78 patents)

7.  Jeffrey A Robl (66 out of 81 patents)

8.  James R Corte (63 out of 65 patents)

9.  Alaric J Dyckman (62 out of 63 patents)

10.  T G Murali Dhar (62 out of 64 patents)

11.  Piyasena Hewawasam (58 out of 61 patents)

12.  Saleem Ahmad (57 out of 59 patents)

13.  Robert Michael Borzilleri (57 out of 60 patents)

14.  Donald J P Pinto (56 out of 78 patents)

15.  R Michael Lawrence (55 out of 61 patents)


Core Competencies:
TLR9 Inhibitors
Therapeutic Proteins
IL-12 Modulators
Anti-PD-1 Antibodies
Heterocyclic Inhibitors
LPA Antagonists
Immunomodulators
Cancer Treatment
Monoclonal Antibodies
Protein Purification
AAV Therapy
IRAK4 Inhibitors

3,699 patents:

1. 12529165 - STABILIZED FIBRONECTIN BASED SCAFFOLD MOLECULES (2026-01-20),
2. 12528865 - Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody (2026-01-20),
3. 12528827 - Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors (2026-01-20),
4. 12528782 - Prodrugs in the modulation of interleukin (2026-01-20),
5. 12527783 - Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide (2026-01-20),
6. 12522561 - Process for synthesizing cationic lipids (2026-01-13),
7. 12521446 - ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES (2026-01-13),
8. 12521390 - Dosage forms for Tyk2 inhibitors (2026-01-13),
9. 12509461 - Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations (2025-12-30),
10. 12492238 - GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES (2025-12-09),
11. 12492217 - Reagents and their use for modular enantiodivergent synthesis of C—P bonds (2025-12-09),
12. 12492202 - Macrocyclic PAD4 inhibitors useful as immunosuppressant (2025-12-09),
13. 12492188 - 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-09),
14. 12492186 - BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS (2025-12-09),
15. 12492172 - SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS (2025-12-09),
Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines to help patients prevail over serious diseases. With a diverse portfolio of products and a strong pipeline of potential new therapies, Bristol-Myers Squibb is at the forefront of advancing science to improve patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

...
3,699 Patents

#1 in Princeton, NJ

#7 in New Jersey

#113 in US

#239 in the World

...
Princeton, NJ, United States of America

Bristol-Myers Squibb Compnay

Forward Citations = 45,969

3,428 inventors:

goldMedal Nicholas A Meanwell (120 out of 141 patents)

silverMedal John E Macor (111 out of 118 patents)

bronzeMedal John F Kadow (106 out of 136 patents)

4.  Paul Michael Scola (85 out of 87 patents)

5.  William R Ewing (70 out of 85 patents)

Please report any incorrect information to support@idiyas.com
Loading…